Researchers find new, more accurate way to detect precancerous and curable-stage colorectal cancer

October 23, 2000

DNA Test Could Significantly Change Current Screening Methods

ROCHESTER, MINN. -- Mayo Clinic researchers working in collaboration with scientists at EXACT Laboratories, Inc. of Maynard, Mass have developed a new, non-invasive test that was 91 percent sensitive for detecting cancer throughout the colon, according to a study released today in the journal Gastroenterology. Each year, 56,000 people in the United States die from cancer of the colon and rectum.

Although about two years away from becoming widely available for public use, Mayo Clinic researchers believe this new method could significantly change the way screening for colorectal cancer is done. Most importantly, they think this new detection method may save thousands of lives annually.

Requiring a stool specimen, the EXACT detection method involves analyzing DNA that's shed from the surface of colorectal tumors and excreted in the stool. Measuring specific DNA abnormalities that are unique to precancerous polyps and early stage cancer results in high accuracy of detection.

"This new, non-invasive test safely and accurately detected curable-stage cancer of the colon and rectum," says David Ahlquist, M.D., a Mayo Clinic gastroenterologist and lead researcher on the study.

"Furthermore, the method detected precancerous polyps," says Dr. Ahlquist. "That's important because by detecting polyps and endoscopically removing them, we know that colorectal cancer can be prevented."

The next step is for the DNA colorectal cancer test to undergo another phase of clinical trials, scheduled to begin this January. Meanwhile, Mayo Clinic physicians encourage people age 50 years and older to follow their physicians' advice and the current recommendations for screening.

According to Dr. Ahlquist, the DNA colorectal cancer test shows promise for supplanting the fecal blood test, an often used but confounding screening test for finding blood in the stool.

"A major problem with the fecal blood test is that as many as 5 to 10 percent of the screened individuals have a false-positive, or incorrect, reading from the test," says Dr. Ahlquist. "This means that one in every 10 to 20 people screened has to unnecessarily undergo a colonoscopy, a costly and invasive medical procedure, to further evaluate the colon.

"Another problem with the fecal blood test is that blood in the stool is not present with many early stage colorectal cancers, nor with the vast majority of polyps," he added.

Colorectal cancer is the second leading cause of malignant death in the United States, accounting for more than 10 percent of all cancer deaths. Annually, 130,000 new cases of colorectal cancer are diagnosed. Over their lifetime, about one in 18 people gets colorectal cancer.

The EXACT scientists developed the technology for this new detection method, which includes novel techniques for recovering human DNA from stool and for measuring a number of tumor-specific DNA alterations.

The initial double-blind study involved analysis of DNA in stool specimens from 61 patients. Unknown to the EXACT scientists performing the test, 22 of the patients had been previously diagnosed with colorectal cancer, 11 of the patients had large pre-cancerous polyps and 28 of the patients had normal colons.

The new DNA colorectal cancer test detected 91 percent of the colorectal cancers and 73 percent of the polyps. There were no incorrect readings among any of the patients with a normal colon.

The collaborative study demonstrated the feasibility of DNA stool analysis as a screening approach and paved the way for a three-year clinical trial. The upcoming clinical trial will be funded by a $4.9 million grant from the National Cancer Institute. Dr. Ahlquist will lead the research effort and Mayo Clinic will be the principle site for the clinical trial.

The DNA colorectal cancer test has several patient-friendly features. An individual can provide a stool specimen in the privacy of their own home by using a special kit that fits on the toilet seat. The DNA test involves no dietary or medication restrictions. Furthermore, in contrast to all invasive screening methods used for colorectal cancer detection, no bowel preparation is needed for the test.

The DNA test also detects tumors and polyps throughout the entire colon, whereas sigmoidoscopy, another invasive detection method, inspects only the lower portion of the colon.

Although the up-front costs of the DNA colorectal cancer test are expected to be more than that of a fecal blood test, Dr. Ahlquist says that in the long run the DNA method could be more cost-effective.

"Because of the high rate of accuracy, the DNA colorectal cancer test could require fewer, unnecessary colonoscopies to be performed," he says. "That will mean a savings in health care expenses because having a colonoscopy in this country currently costs anywhere from $1,000 to $2,500."

He adds that "Costly operations to remove colorectal cancers also may be reduced if the new method leads to more effective detection of precancerous polyps."

"Most important, the new DNA colorectal cancer test has the potential to significantly reduce the morbidity and mortality of colorectal cancer," says Dr. Ahlquist. "Colorectal cancer is largely preventable and curable if detected early."
-end-
Laurel J. Kelly
Division of Communications
Ozmun East 6
Phone 507-538-1092
Fax 507-284-8713




Mayo Clinic

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.